Yahoo Finance

Lyra Therapeutics Reports Positive Results from the ENLIGHTEN 2 Phase 3 Trial of LYR-210 Achieving Statistically Significant Results for Primary and Key Secondary Endpoints in ...

WATERTOWN, Mass., June 02, 2025 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (“Lyra” or the “Company”), a clinical-stage biotechnology company developing long-acting, anti-inflammatory ...
Nasdaq

Lyra Therapeutics Reports Positive ENLIGHTEN 2 Trial Results for LYR-210 in Chronic Rhinosinusitis Treatment

Lyra's LYR-210 showed significant symptom improvement in CRS patients in the ENLIGHTEN 2 trial, meeting primary and secondary endpoints. Lyra Therapeutics announced positive results from their ...
Yahoo Finance

Lyra Therapeutics Announces Restart of Pivotal Phase 3 ENLIGHTEN II Clinical Trial of LYR-210 in Chronic Rhinosinusitis

WATERTOWN, Mass., April 25, 2023 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (“Lyra” or the “Company”), a clinical-stage biotechnology company developing innovative therapies for the ...